Partnership plans trial of antidote to Factor Xa inhibitors

02/6/2013 | American City Business Journals

Portola Pharmaceuticals has entered a partnership with Bayer HealthCare and Johnson & Johnson's Janssen Pharmaceuticals to support a midstage clinical trial of PRT-4445, a reversal agent for anticoagulant Factor Xa inhibitor drugs. The study will involve patients treated with rivaroxaban.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC